Business Description
Madrigal Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US5588681057
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 5.41 | |||||
Equity-to-Asset | 0.63 | |||||
Debt-to-Equity | 0.29 | |||||
Debt-to-EBITDA | -0.33 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -13 | |||||
3-Year EPS without NRI Growth Rate | -15.2 | |||||
3-Year FCF Growth Rate | -19.5 | |||||
3-Year Book Growth Rate | 9.6 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 18.46 | |||||
9-Day RSI | 27.69 | |||||
14-Day RSI | 35.69 | |||||
6-1 Month Momentum % | 85.89 | |||||
12-1 Month Momentum % | -17.33 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.38 | |||||
Quick Ratio | 5.38 | |||||
Cash Ratio | 5.35 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.6 | |||||
Shareholder Yield % | -1.49 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -212.62 | |||||
ROA % | -99.58 | |||||
ROIC % | -2709.35 | |||||
ROC (Joel Greenblatt) % | -20062.15 | |||||
ROCE % | -134.29 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 10.48 | |||||
Price-to-Tangible-Book | 10.48 | |||||
EV-to-EBIT | -10.98 | |||||
EV-to-Forward-EBIT | -6.39 | |||||
EV-to-EBITDA | -11 | |||||
EV-to-Forward-EBITDA | -6.41 | |||||
EV-to-Forward-Revenue | 47.58 | |||||
EV-to-FCF | -12.17 | |||||
Price-to-Net-Current-Asset-Value | 10.56 | |||||
Price-to-Net-Cash | 10.65 | |||||
Earnings Yield (Greenblatt) % | -9.11 | |||||
FCF Yield % | -7.27 |